List view / Grid view
16 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis in the United States...
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
30 September 2014 | By Roche
Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash...
30 September 2014 | By Roche
Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer...
29 September 2014 | By Roche
Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC...
29 September 2014 | By Roche
Roche announced positive data from the coBRIM Phase III study...
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
2 September 2014 | By Roche
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays...
1 September 2014 | By Roche
Roche announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share...
